Shockingly Accurate: The Newest Medical Device Sniffing Out Cancer

Bloomberg reported last week that University of Pennsylvania researchers are investigating the apparent incredible success of dogs in detecting ovarian cancer early. One dog named Tsunami had a better than 90% success rate in identifying ovarian cancer from tissue samples, which is an incredible result, and she isn't the only one -- a large study found that some dogs were 98% accurate in identifying prostate cancer from urine samples. Of course, more research and testing need to be done, but these are definitely interesting and exciting findings.

Unfortunately, there's no way to invest in cancer-sniffing canines. However, for investors interested in putting their money into early cancer detection, there are some interesting companies that are working to improve our early detection tools.

Exact Sciences  (NASDAQ: EXAS  ) is developing a test called Cologuard, which is a noninvasive, stool-based colorectal screening tool. Cologuard is not mean to replace colonoscopies, but rather to serve as an adjunct to them. With strong clinical data (a 10,000 person phase 3 trial showed that the test successfully identified colorectal cancer 92% of the time) and peak sales estimates in the $1 billion to $2 billion range, this is a test -- and a stock -- worth watching. And Myriad Genetics  (NASDAQ: MYGN  ) has a variety of hereditary cancer risk assessment tools, including Colaris for colon cancer, Melaris for melanoma, and perhaps most famously its BRACanalysis for breast and ovarian cancer. With last quarter's molecular diagnostic testing revenue up 19% to $176 million, this could be an interesting stock to watch.

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson discuss canines and the interesting opportunities Exact Sciences and Myriad Genetics have in the oncology field.

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 04, 2014, at 6:45 PM, LFCHTA wrote:

    EXAS -- Cologuard is not intended to be in addition to colonoscopy as stated; it is to screen average risk patients for those who should go on to colonoscopy. Thus, it will eliminate many colonoscopies, and even more important, help to identify CRC earlier ... when it is eminently more treatable.

    R.O Wood

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2978507, ~/Articles/ArticleHandler.aspx, 12/19/2014 8:13:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement